
Flathead Forge Fund 1 invested in NALA Membranes, whose chlorine-stable membranes could cut industrial water treatment costs by eliminating dechlorination steps.
Flathead Forge Fund 1 has invested in NALA Membranes, a North Carolina developer of chlorine-stable membranes for industrial water purification and reuse, the company said Monday. The size of the investment was not disclosed.
NALA's membranes use sulfonated polysulfone, a material that withstands continuous chlorine exposure. Standard reverse osmosis membranes rely on polyamide, which degrades on contact with chlorine. That forces operators to dechlorinate feed water before it reaches the membranes, then rechlorinate after treatment, or use alternative biocides that are less effective and more expensive.
Biofouling is a major operating cost in industrial reverse osmosis. Microorganisms build up on membrane surfaces, raising pressure requirements and forcing more frequent cleaning. Chlorine is the cheapest and most effective biocide. It cannot be used with conventional membranes. NALA's technology eliminates that trade-off, allowing direct chlorination of the feed water.
The industrial water treatment market spans power generation, food and beverage, pharmaceuticals, and manufacturing. All rely on reverse osmosis for water reuse and discharge compliance. Reducing operating costs by simplifying biofouling control could make water reuse more economical, especially in regions with water scarcity or tightening regulations. NALA's membranes could lower the total cost of water treatment by removing the need for dechlorination equipment and chemicals, and by extending membrane life through reduced cleaning cycles.
Several companies have tried to develop chlorine-stable membranes. Most have struggled with performance trade-offs. NALA's sulfonated polysulfone material maintains salt rejection and flux rates comparable to polyamide, the company said. The membranes are currently in field trials at several industrial sites.
Flathead Forge is a venture fund focused on industrial technologies. Its investment in NALA signals confidence in the membrane's commercial potential. NALA plans to use the capital to expand pilot programs and engage with industrial customers, the company said.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.